Physician profile
Lisa Wright
NPI 1518582287
$7,059.52
in general payments reported to CMS, 2019-2025
21 companies · $705 in 2025
The $705 reported for 2025 was more than what 95% of Pediatrics (Nurse Practitioner) providers received nationally (typical 2025 total: $93.49).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $359 · 2022: $431 · 2023: $373 · 2024: $5,191 · 2025: $705.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,235 · Food and Beverage: $1,804 · Travel and Lodging: $230.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,235.00 |
| Food and Beverage | $1,804.45 |
| Travel and Lodging | $230.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $4,666.56 | 2024 | |
| Insulet Corporation | $500.00 | 2021-2025 | Omnipod, Omnipod |
| Beta Bionics, INC. | $405.24 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Ascendis Pharma Endocrinology INC | $215.04 | 2022-2024 | |
| Dexcom, INC. | $212.01 | 2021-2024 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Novo Nordisk INC | $187.13 | 2021-2025 | Sogroya |
| Medtronic, INC. | $180.27 | 2021-2025 | Minimed 780g |
| Tandem Diabetes Care, INC. | $148.82 | 2022-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Xeris Pharmaceuticals, INC. | $95.07 | 2021-2024 | Gvoke Hypopen |
| Ultragenyx Pharmaceutical INC. | $68.98 | 2021 | |
| Azurity Pharmaceuticals, INC. | $60.89 | 2023-2024 | Gliadel, Triptodur |
| Arbor Pharmaceuticals, INC. | $60.67 | 2021-2022 | |
| Eton Pharmaceuticals, INC. | $56.25 | 2022-2025 | Alkindi, Khindivi, Increlex |
| Sequel Med Tech, LLC | $51.51 | 2025 | Twiist |
| Abbvie INC. | $39.97 | 2023-2024 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $22.33 | 2023 | Strensiq |
| Tolmar, INC. | $21.75 | 2023 | |
| Rhythm Pharmaceuticals, INC. | $18.53 | 2021 | |
| Masimo Corporation | $18.44 | 2023 | Set and Rainbow Set |
| Tolmar Pharmaceuticals, INC. | $16.65 | 2022 | |
| Biomarin Pharmaceutical INC. | $13.41 | 2023 | Voxzogo 1.2mg |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Wright listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.